Paydirt
PL
Insider

Patrick Lamy

Senior VP, Commercial Strategy

Patrick Lamy (Senior VP, Commercial Strategy) filed 5 Form 4 reports in the past 24 months (0 purchases, 5 sales), most often in AKRO. The largest single filing was $340K of AKRO (8,000 sh across 2 lots, as filed), executed May 7 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.1M
shares × price, as filed
Last traded
Jul 1 2025
Filed Jul 3 2025
Open performance
Volume by month
$540K$270K$0Oct 2024Apr 2025Oct 2025Apr 2026Jan 2025 · sells $285KMay 2025 · sells $540KJun 2025 · sells $167KJul 2025 · sells $106K
Buys $0 Sells $1.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 5 filings

Sector per market data · by filing · past 24 months

Most traded names
AKRO AKRO AKRO · 0 buys · 5 sells 5 filings
Recent filings
AKROSALE Akero Therapeutics, Inc. View filing → $106K
2,000 sh × $52.88
Exec Jul 1 2025
Filed Jul 3 2025 · 5:30 PM ET
AKROSALE Akero Therapeutics, Inc. View filing → $167K
3,300 sh × $50.46
Exec Jun 2 2025
Filed Jun 4 2025 · 5:30 PM ET
AKROSALE Akero Therapeutics, Inc. View filing → $200K
4,000 sh × $50.00
Exec May 22 2025
Filed May 23 2025 · 5:30 PM ET
AKROSALE Akero Therapeutics, Inc. View filing → $340K
8,000 sh across 2 lots
Exec May 7 2025
Filed May 9 2025 · 5:30 PM ET
AKROSALE Akero Therapeutics, Inc. View filing → $285K
5,000 sh × $57.03
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET